Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Net Cash Flow (2016 - 2025)

Adma Biologics' Net Cash Flow history spans 13 years, with the latest figure at $26.2 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 59.64% year-over-year to $26.2 million; the TTM value through Dec 2025 reached -$15.5 million, down 129.96%, while the annual FY2025 figure was -$15.5 million, 129.96% down from the prior year.
  • Net Cash Flow reached $26.2 million in Q4 2025 per ADMA's latest filing, up from -$28.9 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $51.6 million in Q4 2022 to a low of -$31.5 million in Q1 2025.
  • Average Net Cash Flow over 5 years is $1.6 million, with a median of -$3.8 million recorded in 2024.
  • Peak YoY movement for Net Cash Flow: surged 741.44% in 2024, then tumbled 1780.29% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at $16.7 million in 2021, then soared by 209.48% to $51.6 million in 2022, then crashed by 144.18% to -$22.8 million in 2023, then surged by 172.09% to $16.4 million in 2024, then surged by 59.64% to $26.2 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Net Cash Flow are $26.2 million (Q4 2025), -$28.9 million (Q3 2025), and $18.7 million (Q2 2025).